SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 272 filers reported holding SAGE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.97 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,415,000 | +15.1% | 7,728 | 0.0% | 0.00% | +33.3% |
| Q1 2019 | $1,229,000 | +78.1% | 7,728 | +7.3% | 0.00% | +50.0% |
| Q4 2018 | $690,000 | -34.3% | 7,200 | -3.2% | 0.00% | -33.3% |
| Q3 2018 | $1,050,000 | -14.6% | 7,437 | -5.3% | 0.00% | 0.0% |
| Q2 2018 | $1,229,000 | +6.9% | 7,850 | +10.0% | 0.00% | 0.0% |
| Q1 2018 | $1,150,000 | -19.2% | 7,137 | -76.9% | 0.00% | -40.0% |
| Q3 2016 | $1,424,000 | +32.0% | 30,916 | -13.7% | 0.01% | +25.0% |
| Q2 2016 | $1,079,000 | -6.0% | 35,816 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,148,000 | -37.9% | 35,816 | +12.9% | 0.00% | -42.9% |
| Q4 2015 | $1,849,000 | +40.0% | 31,716 | +1.6% | 0.01% | +40.0% |
| Q3 2015 | $1,321,000 | -45.0% | 31,216 | -5.2% | 0.01% | -37.5% |
| Q2 2015 | $2,403,000 | +174.0% | 32,916 | +88.6% | 0.01% | +166.7% |
| Q1 2015 | $877,000 | – | 17,456 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |